FDA Approves Everolimus (Afinitor) for Metastatic Breast Cancer
The US Food and Drug Administration (FDA) approved the mTOR inhibitor everolimus (Afinitor) last week for use in postmenopausal women with HER2-negative, hormone-receptor–positive advanced breast cancer patients. Afinitor was approved in ...
FDA Approves Everolimus for Advanced Breast Cancer
FDA approves Afinitor for Advanced Breast Cancer
FDA Adds Afinitor to Treatments for Metastatic Breast Cancer